Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.

Journal of medicinal chemistry - 23 Feb 2023

Blum Andreas, Dorsch Dieter, Linde Nina, Brandstetter Susanne, Buchstaller Hans-Peter, Busch Michael, Glaser Nina, Grädler Ulrich, Ruff Aaron, Petersson Carl, Schieferstein Hanno, Sherbetjian Eva, Esdar Christina

Abstract excerpt

The treatment of gastrointestinal stromal tumors (GISTs) driven by activating mutations in the KIT gene is a prime example of targeted therapy for treatment of cancer. The approval of the tyrosine kinase inhibitor imatinib has significantly improved patient survival, but emerging resistance under treatment and relapse is observed. Several additional KIT inhibitors have been approved; still, there is a high unmet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Neoplasms

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins c-kit

Source

Identifiers

PMID: 36728508
DOI: 10.1021/acs.jmedchem.2c00851

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.PMID 36728508Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure-Activity Relationship (SAR).Semantic proximity Read ↗

Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).Semantic proximity Read ↗

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.Semantic proximity Read ↗

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.Semantic proximity Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

New targets and therapies for gastrointestinal stromal tumors.Semantic proximity Read ↗

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.Semantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.Semantic proximity Read ↗

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.